The company is working with financial advisers to examine the deal, and the company could still remain independent, the Bloomberg story said. The financial advisers also have contact other potential buyers.

The company was founded in 2010 and went public in 2012. Its first drug, Varubi, was approved by the US Food and Drug Administration in October 2015. It's used to treat chemotherapy side effects, such as nausea and vomiting. It's other cancer drug Zejula has been struggling.